Interferon (IFN) was administered intermittently for 6 months to the patients with non-A non-B chronic hepatitis (CHNANB), and the effectiveness of the treatment for improving the hepatic function was evaluated. Of 26 patients with CHNANB, 16 received intermittent IFN therapy (IFN group), and 10 were treated by conventinal therapies without IFN (non-IFN group). All patients were observed for 1 year. IFN was administered once a day at 3 MU in principle (1 MU in some patients and 6 MU in 1 patient) daily for 1 week immediately after the beginning of the therapy and 3 times a week for the subsequent 6 months at the outpatient clinic. The patients were followed up for at least 6 months after completion of the treatment. In the IFN group, the serum GPT level normalized in 11(68.8%) of the 16 patients 1 year after the beginning of the treatment. In these 11 patients (normalized group), HCV-RNA was negative or became negative in 3 of the 6 patients in whom the serum HCV-RNA could be examined. Histological grades of inflammation in the liver were also markedly alleviated in the normalized group. The hepatic function did not normalize in any of the 10 patients in the non-IFN group. These findings indicate that IFN therapy is useful for CHNANB.
Introduction
Since Hoofnagle et al. reported that interferon (IFN) is effective for the treatment of non-A non-B chronic hepatitis (CHNANB)1, the effectiveness of IFN therapy for the treatment of CHNANB has been gradually established through clinical application at various institutions2,3,4). However, no consensus concerning the effects of the therapy has been established yet, and also the optimal dose, the method or the period of IFN administration remains to be clarified.
In this study, we treated patients with CHNANB by the IFN daily for 1 week immediately after the beginning of the therapy and 3 times a week for 6 months, and evaluated the effectiveness of this intermittent IFN therapy for improving the liver function in comparison with conventional non-IFN therapies. The IFN therapy was carried out between July 1988 and March 1991.
Materials and Methods

1) Patients
The subjects consisted of 26 patients who were diagnosed as CHNANB by liver function tests, histological examination of the liver, and evaluation of hepatitis virus markers and who showed persistence of abnormal serum transaminase levels for at least 6 months before the therapy (Table 1) .
2) Methods These 26 patients were divided into two groups, IFN group and non-IFN group. IFN group was consisted of 16 patients who were treated with IFN alone. Non-IFN group was consisted of 10 patients who were treated with conventional medicine such as Stronger Neo-Minophagen C (SNMC) or Shosaikoto only. The subjects were followed up for 1 year.
IFN group
(1) Methods of administration The test drug was interferon-a derived from human lymphoblasts (HLBI, Sumitomo Pharmaceutical). The 3 MU of IFN (1 MU in 2 patients and 6 MU in 1 patient) was administered i.m. once a day daily for 1 week at the beginning of the therapy and 3 times a week for the following 6 months. Most patients were hospitalized for 1 week at the beginning of the therapy.
(2) Observation period The patients were observed for 12 months from the beginning of the therapy and were followed-up for as long as possible without other drugs.
(3) Evaluation of improvements in the liver function The liver function was evaluated according to the serum transaminase levels (GOT, GPT: Karmen Unit) determined after IFN administration. observation period. It elevated again in the remaining 4 during or after the therapy but normalized again and remained normal until the end of the observation period in 2 of these 4 patients. In 1 patient, the serum GPT level elevated during the therapy, but it decreased gradually to a normal level and remained normal for more than 6 months until the end of the observation period. Thus, the serum GPT level was normalized and remained normal in 11 of the 16 patients treated with IFN. No normalization of the serum GPT level was observed in any of the 10 patients of non-IFN group. The patterns of changes in the serum GPT level in IFN group could be classified into 5 types (Fig. 2) . In type I, the serum GPT level decreased rapidly after the beginning of the therapy and remained normal after the end of the administration. In type II, serum GPT temporarily elevated during the therapy but normalized after the end of the therapy. In type III, the serum GPT level decreased during IFN therapy, elevated temporarily after the end of the therapy, but decreased again to normal. In type IV, the serum GPT level decreased during IFN therapy, but elevated after the end of the therapy, and did not improve. In type V, no significant improvement was observed during or after IFN therapy. Changes in the serum GPT level in each patient of IFN group are shown in Figs 3-7 separately for types I-V.
In 8 of the 16 patients, the serum GPT level decreased rapidly after the beginning of INF therapy and remained normal until 6 months after the end of the administration (Type I, Fig. 3 ). In 1 patient, the admininstration was discontinued 13 weeks from the beginning, because the serum GPT level elevated after the beginning of the administration and remained high level. In this patient, the serum GPT level decreased gradually after discontinuation of IFN administration to a normal level and remained normal 6 months after the end of the therapy (Type II, Fig. 4) . In 4 patients, the serum GPT level normalized at least temporarily during the therapy but elevated again. In 2 of these patients, it decreased again and became normal 6 months after the end of the administration (Type III, Fig. 5 ). In the other 2, it elevated again and did not normalize despite slight improvements (Type IV, Fig. 6 ). In the remaining 3 patients, the serum GPT level did not normalize during or after the therapy (Type V, Fig. 7 ). 
Anti-IFN antibody
Anti-IFN antibody was measured in all patients administered IFN at the end of the therapy, but it was not detected in any of the patients.
Side effects
Side effects or abnormal laboratory findings were noted in 7 of the 16 patients. They were fever in 4 patients, malaise in 2, headache and backache in 1 each leukocytopenia in 2, thrombocytopenia in 1, and elevated in serum GOT and GPT in 1.
The therapy could be continued except for the patient who showed elevates in serum GOT and GPT.
Thrombocytopenia was resolved after the end of the therapy, but all the other side effects or abnormal laboratory findings soon disappeared during the therapy.
Discussion
We determined the method to administer IFN in consideration of changes in the 2-5 AS activity, which is an index of the anti-viral effect of IFN. According to Kawaguchi et al6), the 2-5 AS activity in peripheral blood monocytes reaches a peak 1 week after the beginning of daily IFN administration but decreases despite continued IFN administration. Also the 2-5 AS activity is reported to be high level for 48 hours after the administration of IFN. From these findings, IFN was administered daily for the first week, then every other day for 6 months. IFN receptors of peripheral blood monocytes are reported to decrease gradually by daily IFN administration but not to decrease by intermittent administration7). This also supports the advantage of IFN administration every other day.
Concerning the improvements of the liver function, the serum GPT level normalized in 11 of the 16 patients administered IFN, and it remained normal in these 11 patients even after the end of the therapy while it did not normalize in any of the patients in the non-IFN group. Therefore, the IFN therapy is considered to have been effective in our patients. Changes in the serum GPT level in IFN group could be classified into 5 types. Eight patients showed a type I pattern, in which the serum GPT normalized rapidly after the beginning of IFN administration and remained normal. The therapeutic effect of IFN against CHNANB is considered to be derived primarily from the direct antiviral action by the 2-5 oligoadenylate activity8 . If it is so, the liver function is expected to improve soon after the beginning of IFN therapy. In fact, the serum transaminase levels improved rapidly after the beginning of the IFN administration in 8 of the 11 patients in the normalized group. As shown in Fig. 8 , the 2-5 AS activity in the normalized group was significantly higher than in non-normalized group at 1 week after the beginning of IFN administration.
The initial high response of 2-5 AS activity to the IFN will be one of the predictive marker of favorable therapeutic results, but the results of therapy will be influenced by other factors such as the amount of virus, various mediators induced by IFN. In the patient shown in Fig. 4 who belonged to the normal group, the serum GPT level showed no improvements even after the beginning of IFN therapy. In this patient, the administration was disocontinued 13 day after the beginning of the treatment, because of suspectable aggravation of tissue damage. However, the serum GPT level gradually decreased, and normalized 16 weeks after the end of the administration, and remained normal until 54 weeks after the beginning of the administration. Histological studies by liver biopsy during this period showed marked improvements in the histological profile to CIH. Nakano et al.9 observed that the expression of BMG on the hepatocyte membrane did not increase even after the IFN therapy in many patients with CHNANB and that the serum GPT level rapidly decreased after the beginning of IFN administration in such patients. They speculated that the serum GPT normalized rapidly, because IFN reduced the amount of the target antigen of virus-infected cells and prevented destruction of virus-infected hepatocytes by MHC-restricted T cell cytotoxicity. However, the expression of BMG on hepatocyte membrane was increased in a few patients after IFN administration, and the serum GPT level elevated slightly after the beginning of IFN administration in these patients. In the patient shown in Fig. 4 , the serum transaminase levels improved after the end of IFN administration. Therefore, MHC-restricted T cell cytotoxicity may have played a major role in elimination of virus-infected hepatocytes in this patient. In this study the high serum BMG levels continued for a longer period in the non-normalized group than in the normalized group. This may be explained by an enhancement of the T cell cytotoxicity because of the high virus level in hepatocytes.
The therapeutic effects of IFN administration have been evaluated according to normalization of the transaminase levels and improvements in the histological profile of the liver, but are assessed recently also from virological approaches. Changes in the HCV antibody and HCV-RNA levels with the treatment have been introduced as new virological parameters.
In our present study, serum HCV-RNA was measured by the nested PCR method. HCV-RNA was found to be negative in 3 of the 6 patients in whom normalization of the serum GPT level continued even after the therapy. Serum HCV-RNA became negative quickly, often during or soon after the treatment, in patients whose serum GPT level normalized shortly after the beginning of IFN therapy (type I). These findings are considered to be important in determination of the dose and the period of IFN administration.
However, HCV-RNA became temporarily negative but appeared again after completion of the treatment in some patients, or it remained positive while the serum GPT level continued to be normal after the therapy in others. New criteria for evaluation of the therapeutic effects using various.. markers including HCV-RNA are needed in such patients.
Since the serum GPT level elevated again in patients who remained or became positive for HCV-RNA, modifications are needed in the treatment of these patients.
Evaluation of the relationship between the therapeutic effects and the background factors of the patients revealed no clear associations. However, the age, the duration of illness, and the history of transfusion were suspected to be related to the effectiveness of IFN therapy. This point needs further clarification in a larger number of patients. Although the normalized group in this study included fewer patients with a history of transfusion, no difference was observed in the therapeutic effect according to the positivity or negativity for HCV antibody. More detailed investigations are needed concerning the relationship of the therapeutic effects with the pattern of infection or the HCV antibody level, i.e., the amount of infecting virus, as well as the presence or absence of HCV antibody.
In this study we classified the changes of transaminase level into five types after IFN administration and this type of classification has not been reported. The changes of transaminase will be reflected the event occurred in vivo, such as immune responses of the host or viral replications. So we consider that this classification will be useful for determining the adequate dose, duration or readminstrain of IFN.
Our IFN therapy, in which IFN was administered daily for the first week and then 3 times a week, was shown to induce normalization of the serum GPT level in a very high percentage in patients with CHNANB. Moreover, HCV-RNA disappeared from the blood of some of these patients, suggesting the complete cure of type C hepatitis. This may eventually lead to prevention of liver cancer and is considered to contribute greatly to improving the prognosis of type C hepatitis. Furthermore, as this therapy causes no severe side effects, requires hospitalization for only 1 week at the beginning, and can be continued at the outpatient clinic, the reduced burden to the patients is considered to be another advantage of this therapy.
